Close Menu

NEW YORK(GenomeWeb) – Qiagen today announced that it has received a CE-IVD mark for its therascreen EGFR RGQ Plasma PCR kit, a liquid biopsy companion diagnostic to guide treatment for patients with non-small cell lung cancer.

The test, co-developed by Qiagen and AstraZeneca, is intended to help physicians identify which advanced NSCLC patients are more likely to benefit from treatment with AstraZeneca's EGFR inhibitor Iressa (gefitinib) in cases where when a suitable tumor tissue sample is not available.  

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care.